Statins in the treatment and the prevention of the progression of atherosclerosis of patients with coronary heart disease

Cover Page

Cite item

Full Text

Abstract

Statins, the most common drugs to lower lipid levels, are «strategic» products for the treatment of patients with coronary heart disease (CHD), atherosclerosis, having the ability to reduce the cardiovascular and total mortality. This class of drugs can slow down the course of atherosclerosis and makes it more benign. A special place among statin places rosuvastatin (Crestor®, «AstraZeneca») due to his number of advantages of pharmacological and clinical properties. Compared with other statins, he has a far more powerful inhibition of the enzyme by metansulfonilamidnoy group and the most hypolipidemic activity (reduction of LDL cholesterol by 45–50% from baseline) in combination with the good tolerability and economic advantages.

About the authors

T. E Morozova

I.M.Sechenov First MSMU

Email: temorozova@gmail.com
д-р мед. наук, проф., зав. каф. клинической фармакологии и фармакотерапии ФППОВ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ

O. A Vartanova

I.M.Sechenov First MSMU

канд. мед. наук, доц. каф. клинической фармакологии и фармакотерапии ФППОВ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ

References

  1. The Demographic Yearbookof Russia. 2010. Federal State Statistical Service (Rosstat). Moscow, 2010. (Демографический ежегодник России, 2010).
  2. Roger V.L., Go A.S., Lloyd-Jones D.M. et al. Heart Disease and Stroke Statistics 2012 Update: A Report From the American Heart Association Circulation 2012, 125: e2–e220: originally published online 2011 http://circ.ahajournals.org/content/125/1/e2
  3. Диагностика и лечение стабильной стенокардии. Российские рекомендации (II пересмотр). Кардиоваск. терапия и профилактика. 2008; 7 (6). Прил. 4.
  4. Томпсон Г.Р. Руководство по гиперлипидемии.МSD 1991; 255.
  5. Knopp R.H. Drug treatment of lipid disorders. New Engl J Med 1999; 498–511.
  6. Weber C, Erl W, Weber K.S., Weber P.C.: HMG-CoA - reductase inhibitors decrease CD11b expression and CD11b - dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes to endothelium and reduce increased adhevsiveness of monocytes isolated from patients with hypercholesterinemia. J Am Col Cardiol 1997; 30: 1212–27.
  7. Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7: 687–92.
  8. Frenette P.S. Lockin a leukocyte integrin with stastin. New Engl J Med 2001; 345: 1419–21.
  9. Kreuzer J, Bader J, Jahn L et al. Chemotaxis of the monocyte cell line U937: dependence on cholesterol and early mevalonate pathway products. Atherosclerosis 1991; 90: 203–9.
  10. Essing M, Nguyen G, Prie D et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranyl geranylation and Rho proteins. Circ Res 1998; 83: 683–90.
  11. Hirsch M, O'Donnell J.C., Jones P. Rosuvastatin is cost - effective in treating patients tolow - density lipoprotein - cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. Eur J Cardiovasc Prev Rehabil 2005; 12: 18–28.
  12. Nissen S.E., Nicholls S.J., Sipahi I. et al. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis. The ASTEROID Trial.JAMA 2006; 295 (13): 1556–65.
  13. Rubba P, Marotta G, Gentile M. Efficacy and safety of rosuvastatin in the management of dyslipidemia. Vasc Health Risk Manag 2009; 5: 343–52.
  14. GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double - blind, placebo - controlled trial. Lancet 2008; 372: 1231–9.
  15. Kjekshus J, Apetrei E, Barrios V et al. for the CORONA Group. Rosuvastatin in Older Patients with Systolic Heart Failure. N Engl J Med 2007; 357: 2248–61.
  16. Ridker P.M., Danielson E, Fonseca F.A.H. et al. for the JUPITER Study Group. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med 2008; 359: 2195–207.
  17. Kiran K, Khush, Waters D. Higher dose of potent statin better for high - risk patients. Cleveland Clinic J Med 2004; 1 (8): 609–16.
  18. VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel. Reversal and PROVE-AT. Updated versions may be found http://www.vapbm.org april 2004.
  19. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32 (14): 1769–818.
  20. Диагностика и коррекция липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации (V пересмотр). Рос. журн. 2012; 4 (96). Прил. 1.

Copyright (c) 2013 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies